Low-dose methotrexate-induced pancytopenia
Authors:
- 25 April 2006
- journal article
- research article
- Published by Springer Nature in Clinical Rheumatology
- Vol. 26 (1) , 84-87
Abstract
Methotrexate (MTX) has gained wide acceptance among both patients and rheumatologists due to its efficacy and safe therapeutic window in a variety of inflammatory rheumatological disorders. However, it has the potential to cause serious, life-threatening complications and even mortality. In the present series, we have reviewed our data of five patients who developed serious pancytopenia after the use of MTX, including one who died. Two of these resulted from prescription errors by primary care physicians. The clinical, laboratory, and outcome profile of all five cases are discussed with a brief review of the literature about MTX-induced pancytopenia. There is an urgent need to increase awareness in primary care physicians, patients, and pharmacists toward informed prescribing, dispensing, and monitoring of MTX to prevent such mishaps in the future.Keywords
This publication has 6 references indexed in Scilit:
- Pancytopenia induced by low‐dose methotrexate. A study of the cases reported to the Finnish Adverse Drug Reaction Register from 1991 to 1999Scandinavian Journal of Rheumatology, 2005
- Methotrexate-induced pancytopenia: serious and under-reported? Our experience of 25 cases in 5 yearsRheumatology, 2005
- Leflunomide-Associated Pancytopenia With or Without MethotrexateAnnals of Pharmacotherapy, 2004
- Low dose methotrexate and bone marrow suppressionBMJ, 2003
- THE REMARKABLE SPECTRUM OF METHOTREXATE TOXICITIESRheumatic Disease Clinics of North America, 1997
- Pancytopenia secondary to methotrexate therapy in rheumatoid arthritisArthritis & Rheumatism, 1996